-
Google Says Its AI Sometimes Outperforms Human Doctors In Detecting Cancer
Thursday, January 2, 2020 - 3:05pm | 443Read More...Which is better at detecting breast cancer: Google's artificial intelligence system or human doctors? According to the Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) unit, it can match or outperform radiologists, The Wall Street Journal reported Wednesday. Google's AI Data Google...
-
10 Biopharmaceutical Companies Trying To Cure Cancer
Saturday, August 24, 2019 - 1:46pm | 1041Read More...Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated at an astounding $1.11 trillion in size. Every year, billions are spent on the...
-
Genmab IPO: What You Need To Know
Monday, July 15, 2019 - 12:36pm | 368Read More...An OTC-listed large-cap biotech is seeking a main exchange listing, and it offers scope for investing in a proven biotech with two commercial partnered products on the market and more in the pipeline. The IPO Terms Copenhagen, Denmark-based GENMAB A/S/S ADR (OTC: GMXAY) has filed for offering 27.80...
-
Johnson & Johnson Falls On Report Of Justice Department Probe
Friday, July 12, 2019 - 2:47pm | 490Read More...Shares of Johnson & Johnson (NYSE: JNJ) were trading lower Friday after Bloomberg reported that the Justice Department has launched a criminal probe into the company. What Happened The investigation is focused on whether J&J deceived the public about the risk of cancer linked to its...
-
BridgeBio Pharma IPO: What You Need To Know
Wednesday, June 26, 2019 - 7:46am | 470Read More...The week will see the listing of a late entrant into the arena, but it nonetheless has an impressive pipeline of investigational assets targeting genetic diseases. The IPO Terms BridgeBio Pharma (NASDAQ: BBIO),founded in 2015 and headquartered in Palo Alto, California, is set to offer 15 million...
-
What's Triggering The Rise In Mirati Shares?
Thursday, May 16, 2019 - 10:47am | 286Read More...Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN) KRAS G12C inhibitor abstract showed promising data at a huge cancer conference. What Happened Amgen showcased its oncology...
-
Johnson & Johnson's Asbestos Woes: Experts Speak Up
Monday, December 17, 2018 - 12:05pm | 519Read More...After a 10 percent drop Friday, Johnson & Johnson (NYSE: JNJ) opened Monday’s session down another 2 percent following last week’s Reuters report that the company has known about asbestos contamination in its baby powder for decades. While the potential for legal and regulatory...
-
Novartis To Buy Endocyte In $2.1B Deal
Thursday, October 18, 2018 - 9:06am | 311Read More...Endocyte, Inc. (NASDAQ: ECYT) on Thursday announced its $2.1-billion cash sale to Novartis AG (NYSE: NVS). The deal values Endocyte at $24 per share, representing a 54-percent premium from the firm’s $15.56 Wednesday closing price. Why It’s Important Endocyte's radioligand...
-
Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints
Monday, June 25, 2018 - 10:29am | 320Read More...Merrimack Pharmaceuticals Inc (NASDAQ: MACK) plunged more than 30 percent Monday after management discontinued the development of MM-141. The drug’s Phase 2 trial for MM-141 in front-line metastatic pancreatic cancer did not meet primary or secondary endpoints. Why It’s Important...
-
Investors Should Own Agios For 'The Next Several Years,' Analyst Says
Thursday, May 31, 2018 - 4:04pm | 385Read More...Agios Pharmaceuticals Inc (NASDAQ: AGIO), a pharmaceutical company that focuses on the field cellular metabolism to treat cancer and rare genetic diseases, is a stock investors should "own for the next several years," according to Piper Jaffray. The Analyst Piper Jaffray's Tyler M....
-
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Tuesday, May 29, 2018 - 3:44pm | 372Read More...G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...
-
Valeant Stock Moves Higher After FDA Approves Bowel Cleanser
Monday, May 7, 2018 - 10:53am | 334Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares gained 2 percent Monday morning after the company confirmed the Food and Drug Administration approved its bowel-cleansing preparation product. What Happened Valeant said the FDA granted approval for PLENVU, the company's polyethylene...
-
Exclusive: Ziopharm Oncology CEO Wants To Disrupt The CAR-T Supply Chain
Monday, April 16, 2018 - 8:11am | 1401Read More...Ziopharm Oncology Inc. (NASDAQ: ZIOP) has two goals. One is to disrupt the narrative around recurrent glioblastomas. The other is to disrupt the entire pharmaceutical supply chain. The latter pursuit isn’t just a B2B revenue opportunity, it's meant to alleviate cost barriers to critical...
-
NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
Monday, April 9, 2018 - 2:24pm | 355Read More...NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY) announced disappointing results from a study of the similar therapy epacadostat. The Analyst Baird Equity Research's Michael Ulz...
-
Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial
Monday, April 9, 2018 - 10:29am | 422Read More...NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...
